Eminence Capital LP Invests $225.26 Million in Tenet Healthcare Corporation $THC

Eminence Capital LP bought a new stake in Tenet Healthcare Corporation (NYSE:THC) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,109,450 shares of the company’s stock, valued at approximately $225,263,000. Tenet Healthcare makes up approximately 2.7% of Eminence Capital LP’s investment portfolio, making the stock its 11th biggest holding.

A number of other hedge funds and other institutional investors also recently made changes to their positions in THC. William B. Walkup & Associates Inc. bought a new stake in shares of Tenet Healthcare in the 3rd quarter valued at approximately $32,000. Westside Investment Management Inc. raised its position in Tenet Healthcare by 100.0% during the third quarter. Westside Investment Management Inc. now owns 192 shares of the company’s stock valued at $39,000 after acquiring an additional 96 shares in the last quarter. Trust Co. of Vermont bought a new stake in Tenet Healthcare in the third quarter worth approximately $41,000. Canada Pension Plan Investment Board bought a new position in shares of Tenet Healthcare during the 2nd quarter valued at $35,000. Finally, Geneos Wealth Management Inc. lifted its stake in shares of Tenet Healthcare by 50.9% in the 2nd quarter. Geneos Wealth Management Inc. now owns 264 shares of the company’s stock valued at $46,000 after purchasing an additional 89 shares during the last quarter. 95.44% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on THC. Royal Bank Of Canada raised their target price on Tenet Healthcare from $253.00 to $277.00 and gave the company an “outperform” rating in a report on Thursday, February 12th. Leerink Partners increased their price objective on Tenet Healthcare from $255.00 to $264.00 and gave the company an “outperform” rating in a report on Friday, February 20th. Wall Street Zen upgraded Tenet Healthcare from a “buy” rating to a “strong-buy” rating in a report on Sunday, March 1st. KeyCorp increased their price target on Tenet Healthcare from $225.00 to $250.00 and gave the company an “overweight” rating in a report on Thursday, February 12th. Finally, Guggenheim boosted their price objective on shares of Tenet Healthcare from $271.00 to $283.00 and gave the stock a “buy” rating in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $250.56.

Insider Buying and Selling

In other Tenet Healthcare news, Director Nadja West sold 2,178 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price of $197.47, for a total transaction of $430,089.66. Following the completion of the transaction, the director directly owned 28,480 shares in the company, valued at $5,623,945.60. This represents a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Paola M. Arbour sold 6,500 shares of Tenet Healthcare stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $238.43, for a total value of $1,549,795.00. Following the transaction, the executive vice president directly owned 29,291 shares of the company’s stock, valued at approximately $6,983,853.13. The trade was a 18.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 48,695 shares of company stock valued at $11,373,201. 0.81% of the stock is currently owned by company insiders.

Tenet Healthcare Stock Up 1.4%

THC opened at $227.79 on Friday. Tenet Healthcare Corporation has a fifty-two week low of $109.82 and a fifty-two week high of $247.21. The company has a market capitalization of $19.81 billion, a P/E ratio of 14.71, a P/E/G ratio of 1.12 and a beta of 1.39. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.76 and a quick ratio of 1.68. The firm’s fifty day moving average price is $213.46 and its two-hundred day moving average price is $204.15.

Tenet Healthcare (NYSE:THC) last released its quarterly earnings data on Wednesday, February 11th. The company reported $4.70 EPS for the quarter, topping analysts’ consensus estimates of $4.08 by $0.62. The company had revenue of $5.53 billion during the quarter, compared to the consensus estimate of $5.47 billion. Tenet Healthcare had a net margin of 6.60% and a return on equity of 26.33%. The firm’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period last year, the firm earned $3.44 EPS. Tenet Healthcare has set its FY 2026 guidance at 16.190-18.470 EPS. On average, analysts anticipate that Tenet Healthcare Corporation will post 12.24 EPS for the current year.

Tenet Healthcare Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.